Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Lumos Pharma Inc (LUMO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Lumos Pharma Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.64 +0.12    +1.60%
28/06 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US55028X1090 
CUSIP:  55028X109
  • Volume: 1,686
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 7.36 - 7.70
Lumos Pharma Inc 7.64 +0.12 +1.60%
IndustryBiotechnology
SectorHealthcare
Employees

31

Equity Type

ORD

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. Its pipeline features development programs for rare diseases associated with growth hormone deficiencies. Its subsidiaries include NewLink International, BlueLink Pharmaceuticals, Inc, BioProtection Systems Corporation and Lumos Pharma Sub, Inc.

Contact Information

Top Executives

Name Age Since Title
An van Es-Johansson 61 2021 Independent Director
Thomas A. Raffin 74 1999 Lead Independent Director
Lota S. Zoth 61 2012 Independent Director
Chad Allen Johnson 42 2018 Independent Director
Mark A. Bach 64 2021 Scientific Advisory Board Member
Kevin M. Lalande 49 2014 Independent Director
Reiko Horikawa - - Member of Scientific Advisory Board
Joseph S. McCracken 68 2020 Independent Director
George Werther - - Member of Scientific Advisory Board
Peter Clayton - - Member of Scientific Advisory Board
Ron Rosenfeld - - Member of Scientific Advisory Board
Richard J. Hawkins 72 2011 CEO & Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LUMO Comments

Write your thoughts about Lumos Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Episcopolian OptionTrader
Episcopolian1 Oct 10, 2017 9:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$NLNK Indoximod + gemcitabine and nab-paclitaxel for Pancreatic cancer. Phase 2 data due anytime now. I bought upside calls $20
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email